scholarly journals Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristics

Vaccine ◽  
2019 ◽  
Vol 37 (50) ◽  
pp. 7391-7393 ◽  
Author(s):  
Johan Vekemans ◽  
Vasee Moorthy ◽  
Martin Friede ◽  
Mark R. Alderson ◽  
Ajoke Sobanjo-Ter Meulen ◽  
...  
Keyword(s):  
Research And Development ◽  
World Health Organization ◽  
Group B Streptococcus ◽  
World Health ◽  
Product Characteristics ◽  
Maternal Immunization ◽  
Group B ◽  
Health Organization ◽  
Organization Research

scholarly journals The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics

2019 ◽  
Vol 69 (5) ◽  
pp. 877-883 ◽  
Author(s):  
Johan Vekemans ◽  
Fernando Gouvea-Reis ◽  
Jerome H Kim ◽  
Jean-Louis Excler ◽  
Pierre R Smeesters ◽  
...  
Keyword(s):  
Research And Development ◽  
World Health Organization ◽  
Vaccine Efficacy ◽  
Group A Streptococcus ◽  
World Health ◽  
Product Characteristics ◽  
Technology Roadmap ◽  
Development Technology ◽  
Group A ◽  
Health Organization

Abstract Group A Streptococcus (GAS) infections result in a considerable underappreciated burden of acute and chronic disease globally. A 2018 World Health Assembly resolution calls for better control and prevention. Providing guidance on global health research needs is an important World Health Organization (WHO) activity, influencing prioritization of investments. Here, the role, status, and directions in GAS vaccines research are discussed. WHO preferred product characteristics and a research and development technology roadmap, briefly presented, offer an actionable framework for vaccine development to regulatory and policy decision making, availability, and use. GAS vaccines should be considered for global prevention of the range of clinical manifestations and associated antibiotic use. Impediments related to antigen diversity, safety concerns, and the difficulty to establish vaccine efficacy against rheumatic heart disease are discussed. Demonstration of vaccine efficacy against pharyngitis and skin infections constitutes a key near-term strategic goal. Investments and collaborative partnerships to diversify and advance vaccine candidates are needed.

scholarly journals Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017

Vaccine ◽  
2019 ◽  
Vol 37 (50) ◽  
pp. 7408-7418 ◽  
Author(s):  
Sami L. Gottlieb ◽  
Birgitte K. Giersing ◽  
Julian Hickling ◽  
Rebecca Jones ◽  
Carolyn Deal ◽  
...  
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
World Health Organization ◽  
World Health ◽  
Meeting Report ◽  
Product Characteristics ◽  
Health Organization ◽  
Simplex Virus

scholarly journals Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: Key considerations from World Health Organization consultations

Vaccine ◽  
2020 ◽  
Vol 38 (2) ◽  
pp. 135-142 ◽  
Author(s):  
Johan Vekemans ◽  
Michael James Brennan ◽  
Mark Hatherill ◽  
Lewis Schrager ◽  
Bernard Fritzell ◽  
...  
Keyword(s):  
World Health Organization ◽  
Treatment Outcomes ◽  
Tuberculosis Treatment ◽  
World Health ◽  
Product Characteristics ◽  
Therapeutic Vaccines ◽  
Health Organization

scholarly journals Population-based surveillance for bacterial meningitis in the Dominican Republic: implications for control by vaccination

2000 ◽  
Vol 125 (3) ◽  
pp. 549-554 ◽  
Author(s):  
E. GOMEZ ◽  
M. PEGUERO ◽  
J. SANCHEZ ◽  
P. L. CASTELLANOS ◽  
J. FERIS ◽  
...  
Keyword(s):  
Bacterial Meningitis ◽  
Dominican Republic ◽  
Group B Streptococcus ◽  
Case Series ◽  
Population Based ◽  
Incidence Rates ◽  
World Health ◽  
Laboratory Methods ◽  
Group B ◽  
Health Organization

Quantifying the local burden of disease is an important step towards the introduction of new vaccines, such as Haemophilus influenzae type b (Hib) conjugate vaccine. We adapted a generic protocol developed by the World Health Organization for population-based surveillance of bacterial meningitis. All hospitals that admit paediatric patients with meningitis in the National District, Dominican Republic were included in the system and standard laboratory methods were used. The system identified 111 cases of confirmed bacterial meningitis. Hib was the leading cause of bacterial meningitis, followed by group B streptococcus, S. pneumoniae, and N. meningitidis. Unlike hospital-based case series, this population-based system was able to calculate incidence rates. The incidence of Hib meningitis was 13 cases per 100 000 children < 5 years old. The data from this study were used by the Ministry of Health to support the introduction of routine Hib vaccination and will be used to monitor its effectiveness.

Sign in / Sign up

Export Citation Format

Share Document